153 Therapeutics, Inc.
June 24, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Brain Health
153 Therapeutics is a UCSF spinout developing a novel small-molecule therapy for Parkinson’s Disease. The approach targets Nurr1, a nuclear receptor that plays a central role in restoring dopamine production and reducing neuro-inflammation and oxidative stress in the brain. A disease model study showed strong and statistically significant treatment responses, and further optimization has produced a lead compound with a favorable pharmacology and safety profiles. Progress to date has been funded by the NIH, UCSF’s Innovation Ventures program, and the Michael J Fox Foundation for Parkinson’s Research.
Company HQ City:
San Francisco
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2021
CEO
Peter Noymer, PhD
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}